Test Labs Limited
Registered name: TEST LABS LIMITED
Part of Specialist Health Solutions Limited groupTest Labs Limited does not publish its revenue or profit. Its accounts to 31 Dec 2024 show net assets of -£96.6k and 12 employees.
Test Labs Limited did not publish its revenue or profit — small companies aren’t required to file a profit & loss account. Its accounts for the year to 31 Dec 2024 showed net assets of −£96.6k and 12 employees. The company is classified under “research and experimental development on biotechnology” and is based in Peterborough; we hold 3 years of its filed accounts.
- Status
- Active
- Location
- Peterborough, East of England
- Age
- 5 yrs · since 2021
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “Specialist Health Solutions Limited”
Key figures
Revenue not disclosed
Test Labs Limited’s accounts for the year to 31 Dec 2024 contain a balance sheet but no profit & loss account, so its revenue and profit are not public. UK small and micro-entity companies are not required to publish a P&L — this is normal and says nothing about how the business is performing.
We never estimate revenue. Below you’ll find the balance-sheet figures that were filed — useful as indirect signals of momentum, but they are not revenue or profit.
- Employees
- 12
- Net assets
- −£96.6k
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2022 | 31 Dec 2023 | 31 Dec 2024 |
|---|---|---|---|
| Disclosure | No P&L | No P&L | No P&L |
| Profit & loss | |||
| Revenue (turnover) | — | — | — |
| Profit (best available) | — | — | — |
| Employees (average) | — | 5 | 12 |
| Ratios | |||
| Profit margin | — | — | — |
| Growth (year on year) | |||
| Headcount growth | — | — | ▲140% |
| Balance sheet — indirect signals, not revenue | |||
| Cash at bank | — | £121k | £186k |
| Net assets | £100 | £47.5k | −£96.6k |
| Fixed assets | — | £748k | £769k |
| Current assets | £100 | £891k | £807k |
| Debtors | £100 | £145k | £162k |
| Source | FullAccounts · bulk data Dec 2024 | FullAccounts · bulk data Dec 2024 | FullAccounts · bulk data Jul 2025 |
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- ▼304%
- Now −£96.6k
- Cash at bank
- ▲53%
- Now £186k
- Headcount
- ▲140%
- Now 12
- Deferred income
- —
- Now —
- Fixed assets
- ▲3%
- Now £769k
Group structure
Ownership chain
- Specialist Health Solutions Limitedultimate parent75–100%
- Test Labs Limitedthis company
Bands show the share of ownership each company holds in the one below it.
Sister companies (10)
- Ashurst Associates LimitedFigures not disclosed
- Clinocall LimitedFigures not disclosed
- Edu-Lab LimitedFigures not disclosed
- Health Spaces LimitedFigures not disclosed
- Inivos LimitedRev. — · Profit −£12.7m
- Inivos UK LimitedFigures not disclosed
- Scichem LimitedFigures not disclosed
- Stradbroke Holdings LimitedFigures not disclosed
- Supply Source LimitedFigures not disclosed
- Vitta Group LimitedFigures not disclosed
From the Persons with Significant Control register (corporate controllers only).
Similar profitable businesses
- Astex Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £404m
- Profit
- £283m
- Staff
- 183
- Amphista Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £33.9m
- Profit
- £19.8m
- Staff
- 56
- Charles River U.K. LimitedKent · Research and experimental development on biotechnology
- Revenue
- £22.2m
- Profit
- £18.8m
- Staff
- 129
- Qiagen Manchester LimitedManchester · Research and experimental development on biotechnology
- Revenue
- £53.7m
- Profit
- £11.8m
- Staff
- 239
- Alchemab Therapeutics LtdLondon · Research and experimental development on biotechnology
- Revenue
- £30m
- Profit
- £8.3m
- Staff
- 55
- Ligand UK Development LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £8.7m
- Profit
- £6m
- Staff
- —
Sources
Latest figures from FullAccounts for the year to 31 Dec 2024, from the Companies House accounts bulk data published Jul 2025. Spotted an error? Request a correction.
Updated from Companies House on 12 Oct 2026
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.